Results 101 to 110 of about 1,181 (167)

From evidence to care delivery: Opportunities and risks in health and science policy. A position paper of the Association of the Scientific Medical Societies in Germany (AWMF). [PDF]

Ger Med Sci
Wörmann B, Kopp I, Nothacker M, Klar E, Sedlmayr M, Vogeser M, Schliephake H, Treede RD.   +7 more
europepmc   +1 more source

A review of 25 years of National Institute of Health and Care Excellence decision making. [PDF]

J Comp Eff Res
Zhang X, Tikhonovsky N, Ramagopalan SV.
europepmc   +1 more source

Onkologen sind für AMNOG-Evolution [PDF]

Im Focus Onkologie, 2012
openaire   +1 more source

EU HTA Regulation and Joint Clinical Assessment-Threat or Opportunity? [PDF]

J Mark Access Health Policy
Schuster V.
europepmc   +1 more source

Pharmaceutical price comparisons across the European Union and relative affordability in Cyprus [PDF]

, 2016
Petrou, Panagiotis, Vandoros, Sotiris
core   +1 more source

Evidence quality and uncertainties considered in appraisal documents of drugs for rare diseases in England and Germany: a data extraction protocol. [PDF]

BMJ Open
Wiedmann L, Nolte E, Cairns J.
europepmc   +1 more source

Costs are a major driver of antibacterial drug prescriptions in Germany: market analysis from 1985 to 2022. [PDF]

Naunyn Schmiedebergs Arch Pharmacol
Bindel LJ, Seifert R.
europepmc   +1 more source

Examining confidential wholesale margin estimates in European countries for the price negotiation of patented drugs in Germany: a statistical model. [PDF]

Health Econ Rev
An der Heiden I, Schiffhorst G, Müller L, Albrecht M, Bartol A, Wiberny S.   +5 more
europepmc   +1 more source

DDD-costs have a strong influence on antibacterial drug prescription in Germany: a differentiated correlation analysis from 1985 to 2022. [PDF]

Naunyn Schmiedebergs Arch Pharmacol
Bindel LJ, Seifert R.
europepmc   +1 more source